Metabolic Tumor Volumes in Radiation Treatment of Primary Brain Tumors
NCT ID: NCT02006563
Last Updated: 2017-10-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
22 participants
OBSERVATIONAL
2011-06-08
2017-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* If MTV \> CTV, the investigators hypothesize that the difference in volumes (cc) is related to worse clinical outcome. Furthermore, in case of local recurrence, the lesion is located in the MTV area that is outside of the CTV.
* Alternatively, if CTV \> MTV, then the difference in volumes is related to higher treatment toxicity.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* If MTV \> CTV, the investigators hypothesize that the difference in volumes (cc) is related to worse clinical outcome. Furthermore, in case of local recurrence, the lesion is located in the MTV area that is outside of the CTV.
* Alternatively, if CTV \> MTV, then the difference in volumes is related to higher treatment toxicity.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients may be enrolled prior to surgery, after surgical resection or with unresectable tumors.
* Patients must be 18 years or older.
* Patients who do not have metal in the body (e.g. pacemakers, implants) that would preclude them from undergoing MRI/MRS exam
* Patients who do not suffer from claustrophobia (fear of enclosed spaces)
* Karnofsky performance status ≥ 60.
* Patients whose size would allow them to fit into the bore of the MRI instrument.
* Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria
* Inability to undergo MRI/MRS exam because of metal in the head or body, such as implants, pacemaker, or biostimulation device. Claustrophobia (fear of enclosed spaces).
* Karnofsky performance status \< 60.
* Patients too large (\> 300 lbs.) to fit into the bore of the MRI instrument.
* Inability to understand the informed consent document.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Miami
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Radka S. Stoyanova
Research Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Radka Stoyanova, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Miami
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Miami
Miami, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20100809
Identifier Type: -
Identifier Source: org_study_id